Found: 6
Select item for more details and to access through your institution.
Evaluation of the management of PARP inhibitor toxicities in ovarian and endometrial cancer within a multi-institution health-system.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 5, p. 1102, doi. 10.1177/10781552211024728
- By:
- Publication type:
- Article
Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation.
- Published in:
- BMC Cancer, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12885-022-09171-6
- By:
- Publication type:
- Article
DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation.
- Published in:
- Pharmacotherapy, 2020, v. 40, n. 11, p. 1108, doi. 10.1002/phar.2463
- By:
- Publication type:
- Article
Clinical and Financial Impacts of an Ambulatory Oncology Pharmacist-Based Intravenous Chemotherapy Education and Follow-Up Program.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 146
- By:
- Publication type:
- Article
Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.859846
- By:
- Publication type:
- Article